Effects of some class IC antarrhythmic drugs on the human heart rate variability (HRV): a new original methodology to evaluate effectiveness and contraindications of a biochemical compound on the human health. Preliminary results

The effects of three Class IC antiarrhytmic drugs -Encainide, Flecainide, Moricizine -on the human health have been measured and quantified through the measurement of the patient HRV before and after the treatment.The proposition of this HRV-based methodology for validation and follow-ups of pharmaceutical therapies is the true novelty of the research referred in the paper.Some 1000 patients Heart Rate are monitored in the research: in the present paper a preliminary set of results is given for a first group of 120 peoples.The Research is aimed to develop, validate and promote the adoption in the clinical practice of new modern algorithms-borrowed from SMCDS and AI -to supply new extra-ordinary mass-scale diagnostic, preventive and cognitive tools both in the clinical practice and for policy making in the health sector towards an actual PPPM, as well as to suggest a new non-invasive cost effective methodology to monitor the effects of new/old pharmaceutical therapies on a patient and/or to adapt dosages and/or to identify important contraindications.The start point is the simple recording of a patient Heart Rate to analyze its time Variability before and during the therapies, by means of some tenths of HRV markers evaluated by the algorithms above, with the aim to identify therapy's positive and negative effects (or trends towards them) on the pathological status fought by the adopted therapy.The results, even if at a preliminary level, confirm the eligibility of the HRV-based analyses as a powerful new tool to follow up a therapy and its effects on a patient with high specific accuracy and sensibility!Even some well known clinical conclusions are reproduced: for examples the Encainide pro-arrhythmic effect -which is the reason why it is no longer used -is clearly highlighted.In general terms, they show that HRV is a powerful biomarker of the overall body health, not yet adequately exploited, but very promising to become in a near future a powerful PPPM diagnostic tool as well as a significant methodology to monitor the effects of new therapies on a single patient or on entire populations (especially if monitored through cheap wearable devices).